You are on page 1of 13

JOURNAL READING

CHEMOTHERAPY WITH PREOPERATIVE RADIOTHERAPY IN RECTAL CANCER


Jean-Franois Bosset, M.D., Laurence Collette, Ph.D., Gilles Calais, M.D.,Laurent Mineur, M.D., Philippe Maingon, M.D., Ljiljana Radosevic-Jelic, M.D.,Alain Daban, M.D., Etienne Bardet, M.D., Alexander Beny, M.D.,and Jean-Claude Ollier, M.D., for EORTC Radiotherapy Group Trial 22921

BACKGROUND

Until the late 1980 high risk of local and distant recurrences after resection of rectal cancer Preoperative radiotherapy, with the aim of improving local control, has been extensively evaluated Early 1990 postoperative chemoradiotherapy was established as a standard treatment in the United States 1993 EORTC Radiotherapy Group initiated a trial (EORTC 22921) assess whether preoperative chemoradiotherapy followed by postoperative chemotherapy improves overall and progression-free survival

METHODS

RESULTS

DISCUSSION
Adding chemotherapy to preoperative radiotherapy slightly increased the incidence of acute toxic effects but did not affect adherence to radiotherapy, the feasibility of surgery, the rate of postoperative complications, or the rates of adherence to postoperative chemotherapy Chemoradiotherapy resulted in downsizing and down-staging of tumors, as well as changes in their histologic characteristics

...DISCUSSION
the 5-year cumulative incidence of distant metastases was about three times that of local recurrences, indicating that future trials should focus on eradicating micrometastases We conclude that in patients with stage T3 or T4 resectable rectal cancer treated with preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival. Regardless of timing, chemotherapy provides a significant benefit with respect to local control

THANK YOU

You might also like